Education
About Us
Working with TipRanks
Follow Us
Immunotech Biopharm Ltd (HK:6978)
:6978
RESEARCH TOOLSreports
Total Valuation
Immunotech Biopharm Ltd has a market cap or net worth of HK$1.58B. The enterprise value is HK$6.67B.
Market CapHK$1.58B
Enterprise ValueHK$6.67B
Share Statistics
Immunotech Biopharm Ltd has 514,584,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding514,584,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immunotech Biopharm Ltd’s return on equity (ROE) is 14.06 and return on invested capital (ROIC) is -123.86%.
Return on Equity (ROE)14.06
Return on Assets (ROA)-0.33
Return on Invested Capital (ROIC)-123.86%
Return on Capital Employed (ROCE)-1.49
Revenue Per Employee0.00
Profits Per Employee-1.21M
Employee Count154
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immunotech Biopharm Ltd is -5.95. Immunotech Biopharm Ltd’s PEG ratio is -0.30.
PE Ratio-5.95
PS Ratio0.00
PB Ratio40.93
Price to Fair Value-83.60
Price to FCF-59.35
Price to Operating Cash Flow-72.42
PEG Ratio-0.30
Income Statement
In the last 12 months, Immunotech Biopharm Ltd had revenue of 0.00 and earned -186.91M in profits. Earnings per share was -0.36.
Revenue0.00
Gross Profit0.00
Operating Income-198.78M
Pretax Income-186.42M
Net Income-186.91M
EBITDA-148.68M
Earnings Per Share (EPS)-0.36
Cash Flow
In the last 12 months, operating cash flow was -79.52K and capital expenditures -19.65K, giving a free cash flow of -99.17K billion.
Operating Cash Flow-79.52K
Free Cash Flow-99.17K
Free Cash Flow per Share>-0.01
Dividends & Yields
Immunotech Biopharm Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.25
52-Week Price Change-1.60%
50-Day Moving Average3.51
200-Day Moving Average2.96
Relative Strength Index (RSI)42.23
Average Volume (3m)375.67K
Important Dates
Immunotech Biopharm Ltd upcoming earnings date is Aug 22, 2025, TBA Not Confirmed.
Last Earnings DateMar 31, 2025
Next Earnings DateAug 22, 2025
Ex-Dividend Date―
Financial Position
Immunotech Biopharm Ltd as a current ratio of 0.20, with Debt / Equity ratio of 23.08%
Current Ratio0.20
Quick Ratio0.19
Debt to Market Cap0.00
Net Debt to EBITDA-0.47
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immunotech Biopharm Ltd has paid 926.00K in taxes.
Income Tax926.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Immunotech Biopharm Ltd EV to EBITDA ratio is -7.94, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA-7.94
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Immunotech Biopharm Ltd has HK$57.49M in cash and marketable securities with ¥116.46M in debt, giving a net cash position of HK$58.97M billion.
Cash & Marketable SecuritiesHK$57.49M
Total Debt¥116.46M
Net CashHK$58.97M
Net Cash Per ShareHK$0.11
Tangible Book Value Per Share-HK$0.07
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immunotech Biopharm Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast44.88%